Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Sidena 50 mg Tablets
Medicines register · Ireland

Sidena 50 mg Tablets

Authorisation PA0711/170/002 · Rowex Limited,

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 19 Nov 2026
Licence holder
Rowex Limited, (all products →)
Active substance
Sildenafil
Clinical trials
14 clinical trials →
Dosage form
Tablet
Route of administration
Oral use
ATC codes
G04BE, G04BE03
First authorised
09/10/2009
Prescription status
Product not subject to medical prescription
Supply
Supply through pharmacies only
Legal basis
Generic application (Article 10(1) of Directive No 2001/83/EC)

Sildenafil: supply and approvals

48 authorised products on the HPRA list contain Sildenafil. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 19 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 19 Nov 2026)
Germany (BfArM)
1 supply notice, e.g. Sildeagil 100 mg Filmtabletten (22 Jan 2024 to 17 May 2024)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 17 years (since 9 October 2009). The HPRA list marks it as marketed in Ireland.

Other medicines with Sildenafil in Ireland

34 other products on the HPRA list contain Sildenafil, from 10 licence holders; 13 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Sidena 100 mg tabletsRowex Limited,National authorisation (PA)Marketed
Sidena 25 mg tabletsRowex Limited,National authorisation (PA)Marketed
Silcarfil 20 mg film-coated tabletsRowex Limited,National authorisation (PA)Marketed
Sildenafil Accord 100 mg film-coated tabletsAccord Healthcare Ireland LimitedNational authorisation (PA)Marketed
Sildenafil Accord 25 mg film-coated tabletsAccord Healthcare Ireland LimitedNational authorisation (PA)Marketed
Sildenafil Accord 50 mg film-coated tabletsAccord Healthcare Ireland LimitedNational authorisation (PA)Marketed
Sildenafil Clonmel 100 mg film-coated tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Sildenafil Clonmel 20 mg film-coated tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Sildenafil Clonmel 25 mg film-coated tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Sildenafil Clonmel 50 mg film-coated tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Sildenafil Teva 20 mg Film-coated TabletsTeva B.V.National authorisation (PA)Marketed
Sildenvia 50 mg film-coated tabletsAccord Healthcare Ireland LimitedNational authorisation (PA)Marketed

All 35 products with Sildenafil →

Other substances in ATC group G04BE

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 7 other active substances share the group G04BE with this product:

Tadalafil (23) · Alprostadil (4) · VARDENAFIL HYDROCHLORIDE TRIHYDRATE (4) · Sildenafil citrate (3) · Avanafil (3) · Vardenafil (1) · Sildenafil citrate for parenteral use (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Rowex Limited, holds 301 products on the HPRA list, with 139 different active substances; 213 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 20 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.